Carcinoma, Small Cell clinical trials
The registry lists 69 studies for Carcinoma, Small Cell across more than 10 countries. 13 are recruiting or about to start. 40 of them are mainly about Carcinoma, Small Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Carcinoma, Small Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (7) · AHS Cancer Control Alberta (4) · SCRI Development Innovations, LLC (3) · University of Washington (2) · Eli Lilly and Company (2) · Valerio Therapeutics (2) · EpicentRx, Inc. (2) · Mayo Clinic (2)
What is being tested here
Drugs under test in Carcinoma, Small Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Anti-DLL3 Antibody-drug Conjugate BL-M14D1 | 1 | 1 | 1 |
| Cisplatin | 0 | 0 | 3 |
| Topotecan | 0 | 0 | 3 |
| Pemetrexed | 0 | 0 | 3 |
| Pembrolizumab | 0 | 0 | 2 |
| Belinostat | 0 | 0 | 2 |
| Gemcitabine | 0 | 0 | 2 |
| Ipilimumab | 0 | 0 | 1 |
| Nivolumab | 0 | 0 | 1 |
| Cosibelimab | 0 | 0 | 1 |
Drug classes tested here Immune checkpoint inhibitors 5 · Antimetabolites 4 · Antimitotic agents 3
Coming up
7studies finish main data collection within a year
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 7
- Dec 2026Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors · Dana-Farber Cancer Institute
- Dec 2026Quantifying Systemic Immunosuppression to Personalize Cancer Therapy · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Jan 2027LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer · City of Hope Medical Center
- Jun 2027ALG-LungCancerRegistry (SAFRO2202) · Société Algérienne de Formation et de Recherche en Oncologie
- Jul 2027Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer · Roswell Park Cancer Institute
- Sep 2027Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal · Fujian Cancer Hospital
- Oct 2027Penfluridol for Relapsed/Refractory Small Cell Cancers · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Who these studies take
Of the 9 Carcinoma, Small Cell studies recruiting now, 6 (67%) set no upper age limit and 2 (22%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (11%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 8 (89%) | 8 (89%) |
| 30 | 9 (100%) | 9 (100%) |
| 40 | 9 (100%) | 9 (100%) |
| 50 | 9 (100%) | 9 (100%) |
| 65 | 9 (100%) | 9 (100%) |
| 75 | 9 (100%) | 9 (100%) |
| 85 | 7 (78%) | 7 (78%) |
Across all 69 studies, recruiting or not: 13% stop at 75 or younger and 0% at 65; 4% take children; 1% are for women only and 3% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Studies
Recruiting first, then most recently updated. Showing 50 of 69. Browse all 69 → or search them.
- BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)RecruitingNCT07625644Phase 314 countries
- Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote MonitoringRecruitingNCT05500391Phase 21 country
- Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung CancerRecruitingNCT04696575Phase 21 country
- Penfluridol for Relapsed/Refractory Small Cell CancersNot yet recruitingNCT07206563Phase 1/21 country
- ALG-LungCancerRegistry (SAFRO2202)RecruitingNCT071618821 country
- Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the EsophagealNot yet recruitingNCT07155122Phase 2
- Perioperative Immunotherapy for Resectable Limited-Stage SCLCRecruitingNCT07109401Phase 21 country
- JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal CarcinomaRecruitingNCT05173246Phase 21 country
- Quantifying Systemic Immunosuppression to Personalize Cancer TherapyRecruitingNCT056218371 country
- Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLCNot yet recruitingNCT06672133Phase 3
- A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell CarcinomaNot yet recruitingNCT06478264Phase 2
- AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMARecruitingNCT06464068Phase 21 country
- Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior ChemotherapyRecruitingNCT00100256Phase 1/21 country
- A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma PhenotypeCompletedNCT03910660Phase 1/22 countries
- Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR TrialSuspendedNCT04402788Phase 2/31 country
- Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerActive, not recruitingNCT04607954Phase 21 country
- Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsActive, not recruitingNCT03333616Phase 21 country
- Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are MetastaticActive, not recruitingNCT02721732Phase 21 country
- Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT01642251Phase 1/21 country
- Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type PatientCompletedNCT05368207Not applicable1 country
- Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive BiomarkerActive, not recruitingNCT04334941Phase 21 country
- Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLCCompletedNCT02688036Phase 31 country
- Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine CancerWithdrawnNCT07328490Phase 1/21 country
- Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)CompletedNCT054614301 country
- LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung CancerActive, not recruitingNCT04560972Phase 11 country
- A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsTerminatedNCT05551117Phase 29 countries
- Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate CancerTerminatedNCT04926181Phase 21 country
- M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung CancersCompletedNCT03554473Phase 1/21 country
- RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)CompletedNCT02489903Phase 21 country
- Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersActive, not recruitingNCT03212404Phase 19 countries
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT040284791 country
- CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsActive, not recruitingNCT04660929Phase 11 country
- Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung CancerTerminatedNCT05191797Phase 1/21 country
- IMFINZI Study in Patients With Extensive Stage Small Cell Lung CancerCompletedNCT048545901 country
- Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical CancerCompletedNCT02164461Phase 11 country
- RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung CancerTerminatedNCT03699956Phase 31 country
- Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung CancerTerminatedNCT02899728Phase 21 country
- TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)TerminatedNCT02608411Phase 21 country
- A Phase I Study of iPS Cell Generation From Patients With COPDCompletedNCT01860898Not applicable1 country
- BI 2536 Second Line Monotherapy in SCLCCompletedNCT00412880Phase 22 countries
- Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer PatientCompletedNCT00826644Phase 31 country
- Study of Arsenic Trioxide in Small Cell Lung CancerCompletedNCT01470248Phase 21 country
- Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell CarcinomaCompletedNCT02881125Phase 11 country
- Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or MediastinumTerminatedNCT00094978Phase 11 country
- Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung CarcinomaTerminatedNCT02034123Phase 13 countries
- A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and EtoposideTerminatedNCT00537511Phase 1/22 countries
- A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer SpecimensCompletedNCT030927396 countries
- Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung CancerStatus unknownNCT02675088Not applicable1 country
- Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed ChemotherapyStatus unknownNCT03811379Phase 21 country
- Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung CancerCompletedNCT00298896Phase 22 countries